Medigene Croissance future

Future contrôle des critères 1/6

Les bénéfices de Medigene devraient diminuer de 4.1% par an tandis que son chiffre d'affaires annuel devrait croître de 16.1% par an. Le BPA devrait croître de en hausse de 11.7% par an.

Informations clés

-4.1%

Taux de croissance des bénéfices

11.7%

Taux de croissance du BPA

Biotechs croissance des bénéfices	43.0%
Taux de croissance des recettes	16.1%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	08 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation

Jan 03

The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business

Aug 12

Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%

Aug 10

We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

Mar 24

Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

Nov 29

This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO

Jun 17

We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate

Mar 29

How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?

Feb 16

How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?

Dec 23

Prévisions de croissance des bénéfices et des revenus

XTRA:MDG1 - Estimations futures des analystes et données financières antérieures (EUR Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	16	-12	N/A	N/A	1
12/31/2025	10	-14	N/A	N/A	1
12/31/2024	11	-12	N/A	N/A	1
6/30/2024	7	-16	-15	-14	N/A
3/31/2024	7	-16	-15	-15	N/A
12/31/2023	6	-16	-16	-15	N/A
9/30/2023	8	-23	-15	-14	N/A
6/30/2023	9	-29	-15	-13	N/A
3/31/2023	20	-19	-2	-1	N/A
12/31/2022	31	-8	11	12	N/A
9/30/2022	31	1	12	13	N/A
6/30/2022	31	10	14	14	N/A
3/31/2022	21	0	1	2	N/A
12/31/2021	10	-10	-11	-11	N/A
9/30/2021	10	-16	-14	-14	N/A
6/30/2021	9	-22	-17	-17	N/A
3/31/2021	8	-25	-21	-21	N/A
12/31/2020	8	-29	-24	-25	N/A
9/30/2020	9	-25	N/A	N/A	N/A
6/30/2020	9	-23	-26	-27	N/A
3/31/2020	10	-21	N/A	N/A	N/A
12/31/2019	11	-20	-17	-16	N/A
9/30/2019	9	-23	N/A	N/A	N/A
6/30/2019	9	-23	-15	-14	N/A
3/31/2019	8	-19	N/A	N/A	N/A
12/31/2018	8	-21	-10	-10	N/A
9/30/2018	8	-18	N/A	N/A	N/A
6/30/2018	8	-16	-9	-11	N/A
3/31/2018	8	-16	N/A	N/A	N/A
12/31/2017	8	-16	N/A	-21	N/A
9/30/2017	8	-14	N/A	N/A	N/A
6/30/2017	8	-17	N/A	-7	N/A
3/31/2017	8	-12	N/A	N/A	N/A
12/31/2016	7	-9	N/A	-4	N/A
9/30/2016	6	-8	N/A	N/A	N/A
6/30/2016	7	-7	N/A	-14	N/A
3/31/2016	7	-11	N/A	N/A	N/A
12/31/2015	7	-13	N/A	-11	N/A
9/30/2015	11	-11	N/A	-9	N/A
6/30/2015	11	-9	N/A	-8	N/A
3/31/2015	13	-7	N/A	-8	N/A
12/31/2014	13	-6	N/A	-9	N/A
9/30/2014	10	-8	N/A	-9	N/A
6/30/2014	9	-7	N/A	-10	N/A
3/31/2014	8	-9	N/A	-12	N/A
12/31/2013	8	-10	N/A	-12	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: MDG1 devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: MDG1 devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: MDG1 devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de MDG1 ( 16.1% par an) devrait croître plus rapidement que le marché German ( 5.7% par an).

Croissance élevée des revenus: Le chiffre d'affaires de MDG1 ( 16.1% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de MDG1 devrait être élevé dans 3 ans

Medigene Croissance future

Future contrôle des critères 1/6

Informations clés

Mises à jour récentes de la croissance future

Consensus EPS estimates fall by 18%

Medigene AG Reaffirms Revenue Guidance for the Year 2024

Medigene Ag Maintains Earnings Guidance for 2024

Medigene Ag Provides Earnings Guidance for 2024

Medigene AG Maintains Financial Guidance for the Fiscal Year 2023

Medigene AG Provides Revenue Guidance for 2023

Recent updates

Medigene AG Presents Unique Approach for Use of Optimal T Cell Receptors in TCR-Guided Modalities At Cell 2024

Medigene AG Presents Progress on KRAS Library and UniTope & TraCR Technology at ESMO 2024

New minor risk - Share price stability

Consensus EPS estimates fall by 18%

Second quarter 2024 earnings released: €0.15 loss per share (vs €0.17 loss in 2Q 2023)

Medigene AG Reaffirms Revenue Guidance for the Year 2024

Medigene AG Expands Patent Portfolio with the Patent Grant for its NY-ESO-1/LAGE 1a Targeted T Cell Receptor in China

New major risk - Financial position

Medigene AG to Report First Half, 2024 Results on Aug 14, 2024

Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness

New minor risk - Shareholder dilution

Medigene AG, Annual General Meeting, Jun 24, 2024

Medigene AG Presents Preclinical Data on Optimal Affinity TCRs Targeting the Neoantigen Mutant KRAS

Medigene Ag Maintains Earnings Guidance for 2024

Medigene Presents Superior TCR-T Cell Functionality by Inclusion of A Costimulatory Switch Protein

Medigene AG Presents Streamlined 6-Day, High Stemness Tcr-T Therapy Production Process

Medigene AG Presents Favorable Safety Profile of TCR-T Cells with Costimulatory Switch Protein at AACR Annual Meeting 2024

Medigene AG Secures European Patent for Its iM-TCR Technology

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Medigene Ag Provides Earnings Guidance for 2024

Medigene AG to Report Fiscal Year 2023 Results on Mar 28, 2024

New minor risk - Financial data availability

Medigene AG Announces Indication Selection for the Clinical Development of Its Lead 3Rd Generation Tcr-T Therapy Program in Solid Tumors

Here's Why We're Watching Medigene's (ETR:MDG1) Cash Burn Situation

Medigene AG Maintains Financial Guidance for the Fiscal Year 2023

Medigene AG Presents First Pre-Clinical Data of Optimal Affinity TCR Targeting mKRAS G12V Combined with a PD1-41BB Costimulatory Switch Protein Showing

Medigene to Present New Pre-Clinical Data for Pipeline TCR-T Therapies At the ESMO Congress 2023

Medigene AG Provides Revenue Guidance for 2023

New major risk - Financial position

Second quarter 2023 earnings released: €0.17 loss per share (vs €0.097 loss in 2Q 2022)

New minor risk - Share price stability

Full year 2022 earnings released: €0.34 loss per share (vs €0.41 loss in FY 2021)

Medigene AG to Report Q3, 2023 Results on Oct 26, 2023

Price target decreased to €3.90

Medigene AG Maintains Revenue Guidance for the Fiscal Year 2022

The Strong Earnings Posted By Medigene (ETR:MDG1) Are A Good Indication Of The Strength Of The Business

Medigene AG (ETR:MDG1) Analysts Just Trimmed Their Revenue Forecasts By 41%

Price target decreased to €5.95

Medigene AG Announces Appointment of Selwyn Ho as Member of the Executive Management Board with Effect of 25 July 2022

Medigene AG Announces Publication Details Augmentation of PRAME-Specific TCR-4 by PD1-41BB Switch Receptor

Medigene AG to Report Q3, 2022 Results on Nov 02, 2022

We're Hopeful That Medigene (ETR:MDG1) Will Use Its Cash Wisely

No longer forecast to breakeven

Medigene AG Reports Preliminary Efficacy and Immune Monitoring Data of Phase I of Phase I/II MDG1011 Trial in Blood Cancers

Medigene AG Achieves Positive Preliminary Results in Phase I of Phase I/II Trial of TCR-T Therapy MDG1011 in Blood Cancers

Consensus revenue estimates increase to €10.5m

Here's Why We're Not Too Worried About Medigene's (ETR:MDG1) Cash Burn Situation

Price target decreased to €6.73

Medigene's PD1-41BB Switch Receptor Improves TCR-T Cell Functionality Against Solid Tumors

Price target decreased to €6.80

Medigene Confirms Revenue Guidance for 2021

This Is Why Shareholders May Want To Hold Back On A Pay Rise For Medigene AG's (ETR:MDG1) CEO

Medigene AG Provides Earnings Guidance for the Year 2021

Consensus forecasts updated

Advisor has left the company

We're Keeping An Eye On Medigene's (ETR:MDG1) Cash Burn Rate

Full year 2020 earnings released: €1.18 loss per share (vs €0.81 loss in FY 2019)

Medigene AG Announces Executive Changes

Medigene AG to Report Fiscal Year 2020 Final Results on Mar 25, 2021

Price target raised to €8.51

How Much Did Medigene's(ETR:MDG1) Shareholders Earn From Share Price Movements Over The Last Three Years?

Medigene AG Presents Further Encouraging Results from the Follow-Up of Acute Myeloid Leukemia Patients

Medigene AG Announces Discontinuation of MDG1021 Development Program

New 90-day high: €3.92

How Much Is Medigene's (ETR:MDG1) CEO Getting Paid?

Price target lowered to €6.87

Medigene AG Announces Board Changes

Medigene AG, Annual General Meeting, Jun 24, 2021

Medigene AG Provides Update on MDG1011 Phase I/II clinical trial